In vitro effects of erythromycin on RANKL and nuclear factor-kappa B by human TNF-α stimulated Jurkat cells

International Immunopharmacology

Volumn 9, Issue 9, 2009, Pages 1105-1109

  Wu, Lan ^a   Lin, Ji Hong ^a   Bao, Kai ^b   Li, Peng Fei ^a   Zhang, Wei Ge ^b  

^a CHINA MEDICAL UNIVERSITY   (China)

^b SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Anti inflammatory effects; Erythromycin; NF B; Osteoclastogenesis; RANKL

Indexed keywords

ERYTHROMYCIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; OSTEOCLAST DIFFERENTIATION FACTOR; TUMOR NECROSIS FACTOR ALPHA;

ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG INHIBITION; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; LEUKEMIA CELL LINE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; STAINING; T LYMPHOCYTE; WESTERN BLOTTING;

ANTI-INFLAMMATORY AGENTS; APOPTOSIS; CELL PROLIFERATION; CELL SEPARATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; ERYTHROMYCIN; FLOW CYTOMETRY; HUMANS; JURKAT CELLS; LYMPHOCYTE ACTIVATION; MICROSCOPY, FLUORESCENCE; NF-KAPPA B; RANK LIGAND; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; T-LYMPHOCYTES; TRANSCRIPTIONAL ACTIVATION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 67649400312     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.intimp.2009.05.008     Document Type: Article

References (22)

1. Hyo Y., Yamada S., and Harada T. Characteristic cell wall ultrastructure of a macrolide-resistant Staphylococcus capitis strain isolated from a patient with chronic sinusitis. Med Mol Morphol 41 (2008) 160-164
2. Siddiqui J. Immunomodulatory effects of macrolides: implications for practicing clinicians. Am J Med 117 (2004) 26-29
3. Kikuchi T., Hagiwara K., Honda Y., Gomi K., Kobayashi T., Takahashi H., et al. Clarithromycin suppresses lipopolysaccharide-induced interleukin-8 production by human monocytes through AP-1 and NF-kappa B transcription factors. J Antimicrob Chemother 49 (2002) 745-755
4. Cho J.W., Lee K.S., and Kim C.W. Curcumin attenuates the expression of IL-1beta, IL-6, and TNF-alpha as well as cyclin E in TNF-alpha-treated HaCaT cells; NF-kappaB and MAPKs as potential upstream targets. Int J Mol Med 19 (2007) 469-474
5. Tsai H.Y., Lin H.Y., Fong Y.C., Wu J.B., Chen Y.F., Tsuzuki M., et al. Paeonol inhibits RANKL-induced osteoclastogenesis by inhibiting ERK, p38 and NF-kappaB pathway. Eur J Pharmacol 588 (2008) 124-133
6. Ichiyama T., Nishikawa M., Yoshitomi T., Hasegawa S., Matsubara T., Hayashi T., et al. Clarithromycin inhibits NF-κB activation in human peripheral blood mononuclear cells and pulmonary epithelial cells. Antimicrob Agents Chemother 45 (2001) 44-47
7. Aoki Y., and Kao P.N. Erythromycin inhibits transcriptional activation of NF-κB, but not NFAT, through calcineurin-independent signaling in T cells. Antimicrob Agents Chemother 43 (1999) 2678-2684
8. Desaki M., Okazaki H., Sunazuka T., Omura S., Yamamoto K., and Takizawa H. Molecular mechanisms of anti-inflammatory action of erythromycin in human bronchial epithelial cells: possible role in the signaling pathway that regulates nuclear factor-κB activation. Antimicrob Agents Chemother 48 (2004) 1581-1585
9. Desaki M., Takizawa H., Ohtoshi T., Kasama T., Kobayashi K., Sunazuka T., et al. Erythromycin suppresses nuclear factor-kappaB and activator protein-1 activation in human bronchial epithelial cells. Biochem Biophys Res Commun 267 (2000) 124-128
10. Sugiyama Y., Yanagisawa K., Tominaga S.I., and Kitamura S. Effects of long-term administration of erythromycin on cytokine production in rat alveolar macrophages. Eur Respir J 14 (1999) 1113-1116
11. Wu L., Zhang W., Tian L., Bao K., Li P., and Lin J. Immunomodulatory effects of erythromycin and its derivatives on human T-lymphocyte in vitro. Immunopharmacol Immunotoxicol 29 (2007) 587-596
12. Lacey D.L., Timms E., Tan H.L., Kelley M.J., Dunstan C.R., Burgess T., et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93 (1998) 165-176
13. Aubin J.E., and Bonnelye E. Osteoprotegerin and its ligand: a new paradigm for regulation of osteoclastogenesis and bone resorption. Osteoporos Int 11 (2000) 905-913
14. Hofbauer L.C., and Schoppet M. Serum measurement of osteoprotegerin-clinical relevance and potential applications. Eur J Endocrinol 145 (2001) 681-683
15. Grcević D., Lukić I.K., Kovacić N., Ivcević S., Katavić V., and Marusić A. Activated T lymphocytes suppress osteoclastogenesis by diverting early monocyte/macrophage progenitor lineage commitment towards dendritic cell differentiation through down-regulation of receptor activator of nuclear factor-kappaB and c-Fos. Clin Exp Immunol 146 (2006) 146-158
16. Lum L., Wong B.R., Jasien R., Becherer J.D., Erdjument-Bromage H., Schlöndorff J., et al. Evidence for a role of a tumor necrosis factor-alpha (TNF-alpha)-converting enzyme-like protease in shedding of TRANCE, a TNF family member involved in osteoclastogenesis and dendritic cell surviva. J Biol Chem 274 (1999) 13613-13618
17. Kong Y.Y., Feige U., Sarosi I., Bolon B., Tafuri A., Morony S., et al. Activated T-cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 402 (1999) 304-309
18. Udagawa N., Kotake S., Kamatani N., Takahashi N., and Suda T. The molecular mechanism of osteoclastogenesis in rheumatoid arthritis. Arthritis Res 4 (2002) 281-289
19. Redlich K., Hayer S., Maier A., Dunstan C.R., Tohidast-Akrad M., Lang S., et al. Tumor necrosis factor alpha-mediated joint destruction is inhibited by targeting osteoclasts with osteoprotegerin. Arthritis and Rheumatism 46 (2002) 785-792
20. Ren W., Wu B., Peng X., Mayton L., Yu D., Ren J., et al. Erythromycin inhibits wear debris-induced inflammatory osteolysis in a murine model. J Orthop Res 24 (2006) 280-290
21. Ren W., Li X.H., Chen B.D., and Wooley P.H. Erythromycin inhibits wear debris-induced osteoclastogenesis by modulation of murine macrophage NF-kappaB activity. J Orthop Res 22 (2004) 21-29
22. Park C.S., Park Y.S., Park Y.J., Cho J.H., Kang J.M., and Kim S.Y. The inhibitory effects of macrolide antibiotics on bone remodeling in chronic rhinosinusitis. Otolaryngol Head Neck Surg 137 (2007) 274-279